Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Industry Perspective on First-in-Human and Clinical Pharmacology Strategies to Support Clinical Development of T-Cell Engaging Bispecific Antibodies for Cancer Therapy.
Nagaraja Shastri P, Shah N, Lechmann M, Mody H, Retter MW, Zhu M, Li T, Wang J, Shaik N, Zheng X, Ovacik M, Hua F, Jawa V, Boetsch C, Cao Y, Burke J, Datta K, Gadkar K, Upreti V, Betts A. Nagaraja Shastri P, et al. Among authors: retter mw. Clin Pharmacol Ther. 2024 Sep 19. doi: 10.1002/cpt.3439. Online ahead of print. Clin Pharmacol Ther. 2024. PMID: 39295563 Review.
A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade.
DaSilva JO, Yang K, Surriga O, Nittoli T, Kunz A, Franklin MC, Delfino FJ, Mao S, Zhao F, Giurleo JT, Kelly MP, Makonnen S, Hickey C, Krueger P, Foster R, Chen Z, Retter MW, Slim R, Young TM, Olson WC, Thurston G, Daly C. DaSilva JO, et al. Among authors: retter mw. Mol Cancer Ther. 2021 Oct;20(10):1966-1976. doi: 10.1158/1535-7163.MCT-21-0009. Epub 2021 Jul 26. Mol Cancer Ther. 2021. PMID: 34315762 Free PMC article.
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning.
Haber L, Olson K, Kelly MP, Crawford A, DiLillo DJ, Tavaré R, Ullman E, Mao S, Canova L, Sineshchekova O, Finney J, Pawashe A, Patel S, McKay R, Rizvi S, Damko E, Chiu D, Vazzana K, Ram P, Mohrs K, D'Orvilliers A, Xiao J, Makonnen S, Hickey C, Arnold C, Giurleo J, Chen YP, Thwaites C, Dudgeon D, Bray K, Rafique A, Huang T, Delfino F, Hermann A, Kirshner JR, Retter MW, Babb R, MacDonald D, Chen G, Olson WC, Thurston G, Davis S, Lin JC, Smith E. Haber L, et al. Among authors: retter mw. Sci Rep. 2021 Jul 13;11(1):14397. doi: 10.1038/s41598-021-93842-0. Sci Rep. 2021. PMID: 34257348 Free PMC article.
A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
DiLillo DJ, Olson K, Mohrs K, Meagher TC, Bray K, Sineshchekova O, Startz T, Kuhnert J, Retter MW, Godin S, Sharma P, Delfino F, Lin J, Smith E, Thurston G, Kirshner JR. DiLillo DJ, et al. Among authors: retter mw. Blood Adv. 2021 Mar 9;5(5):1291-1304. doi: 10.1182/bloodadvances.2020002736. Blood Adv. 2021. PMID: 33651100 Free PMC article.
Preclinical PET imaging with the novel human antibody 89Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues.
Kelly MP, Makonnen S, Hickey C, Arnold TC, Giurleo JT, Tavaré R, Danton M, Granados C, Chatterjee I, Dudgeon D, Retter MW, Ma D, Olson WC, Thurston G, Kirshner JR. Kelly MP, et al. Among authors: retter mw. J Immunother Cancer. 2021 Jan;9(1):e002025. doi: 10.1136/jitc-2020-002025. J Immunother Cancer. 2021. PMID: 33483343 Free PMC article.
Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5.
Latuszek A, Liu Y, Olsen O, Foster R, Cao M, Lovric I, Yuan M, Liu N, Chen H, Zhang Q, Xiao H, Springer C, Ehrlich G, Kamat V, Rafique A, Hu Y, Krueger P, Huang T, Poueymirou W, Babb R, Rosconi MP, Retter MW, Chen G, Morton L, Zambrowicz B, Cao J, Romano C, Olson WC. Latuszek A, et al. Among authors: retter mw. PLoS One. 2020 May 8;15(5):e0231892. doi: 10.1371/journal.pone.0231892. eCollection 2020. PLoS One. 2020. PMID: 32384086 Free PMC article.
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
Crawford A, Haber L, Kelly MP, Vazzana K, Canova L, Ram P, Pawashe A, Finney J, Jalal S, Chiu D, Colleton CA, Garnova E, Makonnen S, Hickey C, Krueger P, DelFino F, Potocky T, Kuhnert J, Godin S, Retter MW, Duramad P, MacDonald D, Olson WC, Fairhurst J, Huang T, Martin J, Lin JC, Smith E, Thurston G, Kirshner JR. Crawford A, et al. Among authors: retter mw. Sci Transl Med. 2019 Jun 19;11(497):eaau7534. doi: 10.1126/scitranslmed.aau7534. Sci Transl Med. 2019. PMID: 31217340
43 results